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Genome-Wide TOP2A DNA Cleavage is Biased Toward Translocated
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Abstract
Type II topoisomerases orchestrate proper DNA topology, and they are the targets of anti-cancer drugs that
cause treatment-related leukemias with balanced translocations. Here, we develop a high-throughput
sequencing technology to define TOP2 cleavage sites at single-base precision, and use the technology to
characterize TOP2A cleavage genome-wide in the human K562 leukemia cell line. We find that TOP2A
cleavage has functionally conserved local sequence preferences, occurs in cleavage cluster regions (CCRs),
and is enriched in introns and lincRNA loci. TOP2A CCRs are biased toward the distal regions of gene
bodies, and TOP2 poisons cause a proximal shift in their distribution. We find high TOP2A cleavage levels in
genes involved in translocations in TOP2 poison–related leukemia. In addition, we find that a large
proportion of genes involved in oncogenic translocations overall contain TOP2A CCRs. The TOP2A cleavage
of coding and lincRNA genes is independently associated with both length and transcript abundance.
Comparisons to ENCODE data reveal distinct TOP2A CCR clusters that overlap with marks of transcription,
open chromatin, and enhancers. Our findings implicate TOP2A cleavage as a broad DNA damage mechanism
in oncogenic translocations as well as a functional role of TOP2A cleavage in regulating transcription
elongation and gene activation.
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Type II topoisomerases orchestrate proper DNA topology, and they are the targets of anti-cancer drugs that cause treat-
ment-related leukemias with balanced translocations. Here, we develop a high-throughput sequencing technology to define
TOP2 cleavage sites at single-base precision, and use the technology to characterize TOP2A cleavage genome-wide in the
human K562 leukemia cell line. We find that TOP2A cleavage has functionally conserved local sequence preferences, occurs
in cleavage cluster regions (CCRs), and is enriched in introns and lincRNA loci. TOP2A CCRs are biased toward the distal
regions of gene bodies, and TOP2 poisons cause a proximal shift in their distribution. We find high TOP2A cleavage levels
in genes involved in translocations in TOP2 poison–related leukemia. In addition, we find that a large proportion of genes
involved in oncogenic translocations overall contain TOP2A CCRs. The TOP2A cleavage of coding and lincRNA genes is
independently associated with both length and transcript abundance. Comparisons to ENCODE data reveal distinct TOP2A
CCR clusters that overlap with marks of transcription, open chromatin, and enhancers. Our findings implicate TOP2A
cleavage as a broad DNA damage mechanism in oncogenic translocations as well as a functional role of TOP2A cleavage
in regulating transcription elongation and gene activation.
[Supplemental material is available for this article.]
Human type II topoisomerases, of which there are α and β iso-
forms, are central to dynamic changes in DNA topology for repli-
cation, transcription, and chromosome organization and
segregation. They relax, unknot, and untangle DNA by transiently
cleaving and religating both strands of the double helix. Each sub-
unit of the TOP2 homodimer forms a phosphodiester bond with
the base 3′ to the cleavage, creating the cleavage complex, a cova-
lent intermediate with four-base staggered DNA ends tethered by
the enzyme (Pendleton et al. 2014). TOP2A increases during cell
growth and is required for replication (Pendleton et al. 2014). It
also is a member of the BAF complex that decatenates newly repli-
cated sister chromatids during mitosis (Dykhuizen et al. 2013).
TOP2B expression is cell cycle independent (Pendleton et al.
2014).
Roles for both isoforms have been suggested during transcrip-
tion. TOP2B is necessary for transcription of developmentally reg-
ulated genes and nuclear hormone receptor target genes (Ju et al.
2006; Lyu et al. 2006). In a Burkitt lymphoma cell line, dissipation
of supercoiling at transcription start sites of highly expressed genes
was found to be TOP2B dependent (Kouzine et al. 2013). Both iso-
forms were detected at supercoiled domains during transcription
in RPE1 cells (Naughton et al. 2013). TOP2A was identified in
the Pol II complex (Mondal and Parvin 2001). A switch from
TOP2A to TOP2B binding at promoters of long genes during
neuronal differentiation (Tiwari et al. 2012; Thakurela et al.
2013) suggested promoter priming by TOP2A for murine ES cell
differentiation (Thakurela et al. 2013).
Type II topoisomerases are targets of anti-cancer drugs re-
ferred to as “TOP2 poisons” that convert native TOP2 into a toxin
by stabilizing cleavage complexes, which causes DNA strand
breaks and induces apoptosis (Pendleton et al. 2014). TOP2 poi-
sons also cause treatment-related leukemias with balanced translo-
cations of the KMT2A gene and, less often, other loci (Pendleton
et al. 2014). The prevailingmodel of the translocationmechanism
involves misrepair of TOP2-mediated DNA damage (Lovett et al.
2001; Whitmarsh et al. 2003; Mistry et al. 2005; Povirk 2006;
Robinson et al. 2008). Consistent with this model, TOP2 poisons
increase in vitro TOP2 cleavage at or near the breakpoints
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Robinson et al. 2008), and etoposide treatment induced TOP2B
cleavage in a leukemia cell line 3′ in the KMT2A breakpoint cluster
region (bcr) (Cowell et al. 2012). In KMT2A-rearranged (KMT2A-R)
leukemia in infants, maternal-fetal exposures to dietary TOP2 in-
teracting substances (Spector et al. 2005) and an inactivating vari-
ant in NQO1, which detoxifies the TOP2 poison p-benzoquinone
(Wiemels et al. 1999; Smith et al. 2002; Lindsey et al. 2004; Guha
et al. 2008), are predisposing factors.
However, studies of TOP2 have been impeded by lack of a
technology to determine cleavage by these enzymes at single-
base precision in cells genome-wide. A key challenge to surmount
is removal of the covalently attached DNA from TOP2 at the cleav-
age site. Conventional ChIP cannot distinguish noncovalent
TOP2DNA binding from TOP2 covalently bound to DNA in cleav-
age complexes, and most TOP2 DNA binding is noncovalent
(Mueller-Planitz and Herschlag 2007; Lee et al. 2012). General
techniques to map DNA breaks in cells are not TOP2 specific,
have low spatial resolution (Iacovoni et al. 2010; Pang et al.
2015), and may not detect TOP2 cleaved DNA ends protected by
the enzyme (Crosetto et al. 2013; Baranello et al. 2014). A tiling
array of select genomic regions used to analyze murine TOP2B
cleavage did not distinguish double-strand breaks (DSBs) from
single-strand nicks (SSNs) (Sano et al. 2008). Furthermore, in a
cell line study employing TDP2 (Tyrosyl-DNA phosphodiesterase
2) to remove the DNA from TOP2, genome-wide data were not
reported (Cowell et al. 2012).
Here, we develop a platform to detect the sequences at which
TOP2 is actively engaged in cleavage complexes at single-base pre-
cision genome-wide, and apply this technology to characterize
TOP2A cleavage in human K562 leukemia cells.
Results
Optimization of procedure to detect TOP2 cleavage complexes
Following cellular lysis, sonication, and immunocapture of
TOP2A, including that in covalent cleavage complexes (Supple-
mental Fig. S1), we used calf intestinal alkaline phosphatase
(CIP) to hydrolyze the covalent phosphodiester bond between
the DNA and active site tyrosine residue of each TOP2A subunit,
thus releasing the DNA ends at the 3′ sides of cleavage, i.e., +1 po-
sitions in cleavage complexes (Fig. 1A). CIP is a phosphomonoes-
terase commonly used to hydrolyze 5′-phosphate bonds but can
act as a phosphodiesterase. The CIP used here (New England Bio-
labs) has phosphodiesterase activity at 3% the level of its phospho-
monoesterase activity (Igunnu et al. 2011). The exposedDNA ends
became ligation sites for sequencing library adapters to localize
TOP2A cleavage at single-base precision (Fig. 1A).
We mapped TOP2A cleavage complexes after treating K562
cells with vehicle (DMSO), anti-cancer drugs (etoposide or mitox-
antrone), or environmental (p-benzoquinone) or dietary (geni-
stein) TOP2 poisons. A preamplification step was introduced
after the CIP treatment before ligation of adapters to increase sen-
sitivity in the event of limited DNA recovery. Libraries from three
nonamplified and 11 preamplified samples (Supplemental Fig. S1)
yielded 41 million–65 million raw reads each, with 95%–99%
mapping and 68%–72% mapping uniquely to the genome
(GRCh38/hg38) (Supplemental Table S1).
We found strong correlations in read densities for 10-kb win-
dows across the genome between nonamplified and amplified bi-
ological replicates (r = 0.86, DMSO; r = 0.88, etoposide; r = 0.85; p-
benzoquinone) (Fig. 1B, left; Supplemental Fig. S2). Independent
nonamplified and amplified p-benzoquinone–treated replicates
showed similar KMT2A bcr signal profiles (Fig. 1C). Read densities
also correlated tightly between amplified replicates (r = 0.94,
DMSO; r = 0.97, etoposide; r = 0.88, p-benzoquinone; r = 0.84, ge-
nistein) (Fig. 1B, right; Supplemental Fig. S2), indicating high re-
producibility regardless of preamplification. Genomic bases
showing greater than or equal to fourfold signal enrichment in
the 5′ end of mapped reads (i.e., +1 positions of cleavage sites)
with a P-value <0.05 compared with that of the input (Audic and
Claverie 1997) were defined as cleavage sites.
Aggregate analyses of 650 sense-strand nucleotides in four in
vitro cleavage assays (Fig. 1D; Supplemental Figs. S3, S4) identified
77 KMT2A bcr TOP2A cleavage sites also found by sequencing, in-
cluding in a treatment-related leukemia translocation breakpoint
hotspot (Fig. 1D; Whitmarsh et al. 2003). Because of the usage of
naked DNA for the in vitro assays, chromatin determinants of cel-
lular TOP2 cleavage, and greater sensitivity of sequencing, the sites
were not entirely concordant, but the general overlap validates the
phosphodiesterase activity by CIP and detection of bona fide
cleavage complexes at single-base precision. Concordance with lo-
cal base sequence preferences for TOP2 in vitro cleavage (Palumbo
et al. 1994; Capranico and Binaschi 1998) further showed that am-
plification does not alter the precision in cleavage site detection
(Supplemental Fig. S5).
TOP2A cleavage events are SSNs more often than DSBs
Rather than creating a concerted DSB, the two subunits of the
TOP2 homodimer create coordinated nicks on each strand of
DNA, forming a fleeting TOP2-bound cleaved DNA complex
(Zechiedrich et al. 1989). Etoposide occupancy at both scissile
bonds is required for DSBs, and most breaks formed at concentra-
tions relevant to chemotherapy are SSNs (Bromberg et al. 2003).
Consistent with reports in which the vast majority of detected
TOP2 cleavage events were SSNs (Bromberg et al. 2003;
Muslimovic et al. 2009), we found 1.3%–3.4% of TOP2A cleavage
events were DSBs and the remainder were SSNs (Supplemental
Table S1; Supplemental Fig. S2).
Genome-wide characterization of TOP2A cleavage
cluster regions
The KMT2A bcr analyses suggested a clustering of reads (Fig. 1C)
and TOP2A cleavage sites (Fig. 1D; Supplemental Figs. S3, S4) in
compact genomic regions similar to cleavage by yeast Spo11
(Pan et al. 2011). Therefore, we adapted computational methods
for identifying Spo11 hotspots (Pan et al. 2011) to uncover
TOP2A cleavage cluster regions (CCRs; i.e., cleavage sites as de-
fined by criteria above mapping within 200 bp of each other). To
exclude candidates with high background signals from noncleav-
age sites, eachCCRmet further criteria of a 25-ntminimum length
and a total number of reads greater than or equal to fourfold over
input in the same genomic region (Pan et al. 2011).
High concordance in CCR patterns in nonamplified versus
amplified or amplified versus amplified biological replicates
(Supplemental Fig. S6) enabled merging of amplified replicates
for CCR analyses. We identified 310,239, 202,926, 359,486, and
415,312 CCRs inmerged amplified DMSO, etoposide, p-benzoqui-
none, and genistein data sets, respectively. The single amplified
mitoxantrone-treated sample had 182,679 CCRs (Supplemental
Table S1). Most CCRs (75%–90%) were 100–200 nt long (Fig. 3A,
below; Supplemental Fig. S6). Comparisons to existing human sin-
gle-nucleotide polymorphism (SNP) data (The 1000 Genomes
TOP2A-mediated cleavage across the human genome
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Project Consortium2015) indicated lower SNP densities in the 100
nt surrounding TOP2ACCR centers than in the surrounding 10 kb
and, therefore, high genome-wide TOP2A CCR conservation
across the human population (Fig. 2).
We found that TOP2A CCRs were enriched in gene introns
and lincRNAs compared with genomic control regions; fewer
fell in pseudogenes or repetitive elements as annotated by
RepeatMasker (Fig. 3B; Smit et al. 2013–2015), suggesting a prefer-
ence for transcriptionally active regions of the genome. Enrich-
ment at introns but not promoters suggested a potential role of
TOP2A cleavage in relieving torsional stress during transcription
(Fig. 3B).
Figure 1. Approach, reproducibility, and assay validation. (A) TOP2 cleavage complexes detected by sequencing. After TOP2 immunocapture, CIP re-
leases covalently attached TOP2 subunits from DNA at the +1 positions relative to the cleavage, which (+/− preamplification) become 5′ adapter-ligated
ends; 5′ ends from sonication give random signals. Input control (data not shown) is sonicated lysatewith random5′ ends created by sonication. (B) Strong
read count correlations in 10-kb windows between DMSO-treated biological replicates +/− preamplification (Supplemental Table S1). (C ) UCSC Genome
Browser images and KMT2A gene model (http://genome.ucsc.edu/) (Kent et al. 2002) showing similar read distribution in nonamplified and amplified p-
benzoquinone (pBQ)–treated replicates. Black bar indicates bcr. (D) Overlap of TOP2A cleavage sites detected by sequencing with cleavage sites from the
in vitro assay. Vertical line beneath the red arrow in the KMT2A bcr schematic is a translocation breakpoint hotspot from the TOP2A high-throughput se-
quencing assay (bottom, left) and autoradiograph inset from TOP2A in vitro cleavage assay of sense strand of same sequence (bottom, right). Colors indicate
different treatments; symbols, different replicates. Arrows at peaks in sense strand (bottom, left) indicate +1 positions of cleavage sites also found in vitro
(bottom, right, dashes). Connecting lines indicate sites with cleavage detected at +1 positions of both strands by sequencing (bottom, left). Coordinates,
NC_000011.10 (GRCh38/hg38). (VP16) Etoposide. Bars beneath KMT2A bcr schematic, regions from both assays in Supplemental Figures S3 and S4.
Yu et al.
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Certain chromosomes consistently showed more CCRs than
others. Overall, Chr 11 containingKMT2A and 15 of 79 of its trans-
location partner genes showed the highest CCR density compared
with other chromosomes (Fig. 3C; Supplemental Fig. S7).
By gene ontology (GO) analysis of proteins encoded by genes
with TOP2A CCRs, the most enriched category (GO:008152) was
metabolic process, which encompasses cell growth andmacromo-
lecular processes (DNA repair, replication). The second most en-
riched category, cellular process (GO:0009987), contained genes
involved in transcriptional regulation (Fig. 3D).
Genes involved in oncogenic translocations show TOP2A CCR
enrichment
Most translocation breakpoints in cancer overall (91%) (Novo et al.
2007), including KMT2A translocation breakpoints (Felix et al.
2006; Meyer et al. 2013), are in introns. The nonrandom density
by chromosome and CCR intron preference led us to further study
howTOP2A cleavage and translocations are related.KMT2A and its
partner genes comprise the KMT2A recombinome (Meyer et al.
2013). Interestingly, we found that the proportion of KMT2A
recombinome genes containing TOP2A CCRs was significantly
higher than all coding genes (Fig. 4A, left). In accord with the re-
ported precision in the reciprocal breakpoint junctions of KMT2A
translocations in treatment-related leukemias that implicates
DNA DSBs at/near the breakpoints (Lovett et al. 2001; Whitmarsh
et al. 2003; Povirk 2006; Felix 2012), more KMT2A recombinome
genes contained TOP2A DSBs (Fig. 4A, middle) than all coding
genes, particularly with etoposide, the drug most commonly asso-
ciated with KMT2A-R treatment–related leukemia (Felix 2012).
When CCR signal strength, i.e., the number of reads at cleav-
age sites per CCR expressed as hits per 10 million reads (HP10M),
was examined globally, several of the highest CCR signals with p-
benzoquinone treatment were in the KMT2A bcr (Supplemental
Table S2). Also, p-benzoquinone and genistein, which have poten-
tial epidemiologic links to infant leukemia (Wiemels et al. 1999;
Smith et al. 2002; Lindsey et al. 2004; Spector et al. 2005; Guha
et al. 2008), induced TOP2A cleavage in the bcr (Supplemental
Figs. S3, S4). Furthermore, most TOP2A breaks are SSNs (Supple-
mental Fig. S2), and it is well established that paired SSNs on oppo-
site DNA strands and template-directed polymerization of long
overhangs are required to create the KMT2A translocation break-
point junctions with the several-hundred-base sequence duplica-
tions typical of leukemia in infants (Gillert et al. 1999; Raffini
et al. 2002). These findings support amodel inwhichTOP2A cleav-
age triggers KMT2A translocations in both treatment-related and
infant leukemia.
The TOP2 poisons also induced stronger and distinguishable
patterns of TOP2A CCRs compared with DMSO in introns of
other genes besides KMT2A, e.g., PML, RARA, and RUNX1, in
which TOP2-mediated DNA damage from TOP2 poison exposures
has been implicated in leukemia-associated translocations (Fig.
4B–E; Roulston et al. 1998; Smith et al. 1998; Mistry et al. 2005;
Ottone et al. 2009; Felix 2012). Remarkably, compared with all
coding genes, known cancer fusion genes per se (i.e., genes in-
volved in translocations) (Mitelman et al. 2016) also were more
likely to contain TOP2A CCRs (Fig. 4A, right). In addition, we
found high genic TOP2A CCR signal strengths (i.e., average signal
strength of all CCRs within a gene in HP10M) in fusion genes
linked to leukemias more broadly, as well as solid tumors
(Supplemental Table S3; Mitelman et al. 2016).
CCR profiles in coding genes support role of TOP2A cleavage
in transcription elongation
We extracted genome-wide transcript abundance data from two
RNA-seq data sets for K562 cells (Bansal et al. 2014) to investigate
whether TOP2A cleavage is associated with transcription.Whereas
the distribution of coding transcript abundance is bimodal, with
DMSO treatment and each TOP2 poison, we found that coding
genes containing one or more CCRs were significantly enriched
in the peak containing more abundant transcripts (Fig. 5A),
suggesting that TOP2A cleavage may promote higher levels of
transcription.
Existing data for K562 cells (The ENCODE Project Consor-
tium 2012) allowed us to study relationships between TOP2A
CCRs in coding genes and marks of transcription. H3K36me3 is
a mark of actively transcribed genes deposited by the elongating
RNA Pol II–associated methyltransferase SETD2 (Li et al. 2002;
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Figure 2. Regional TOP2A CCR sequence conservation. Lower SNP den-
sity within 100 nt at CCR centers compared with the surrounding 10 kb in
100-nt sliding windows. P < 2.2 × 10−16; Kruskal–Wallis test. Amplified sam-
ples; same treatments merged where applicable (Supplemental Table S1).
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Strahl et al. 2002). With DMSO treatment and each TOP2 poison,
we found that TOP2A-cleaved coding genes hadhigherH3K36me3
and POLR2A (RNA Pol II subunit A) signals compared with those
lacking CCRs (Fig. 5B,C). Because H3K36me3 and POLR2A sites
are distributed across the gene body, these data suggested a role
of TOP2A cleavage in transcription elongation and led us to study
TOP2A CCR distribution along the gene body. In DMSO-treated
and p-benzoquinone–treated cells, the TOP2ACCRs localized pref-
erentially to the middle and 3′ end compared with the very 5′ end
and increased progressively along the gene body (Fig. 5D). In con-
trast, etoposide, mitoxantrone, and genistein caused marked in-
creases in TOP2A CCRs just downstream from the 5′ end and,
thus, altered this distribution compared with CCRs in the absence
of these poisons. Overall, these data suggest that TOP2A cleavage
changes the gene body topology for transcription elongation.
TOP2A cleavage of coding genes is independently associated with
gene length and transcript abundance
Next we examined interrelationships among TOP2A CCR signal
strength, gene length, and transcript abundance. To address
whether genicTOP2ACCRsignal strength is related to gene length,
we divided the genes into four length categories and defined genic
CCR signal strength as the average signal strength of all CCRswith-
in a gene to control for the tendency of longer genes to have more
CCRs due to their increased sequence space. We found significant
increases in CCR signal strength as a function of length category
(<10, 10–49, 50–99, ≥100 kb) (Fig. 6A,B; Supplemental Fig. S8).
We then used the transcript abundance data from the two
RNA-seq data sets for K562 cells (Bansal et al. 2014) to ask whether
gene length and transcript abundance are related. The small nega-
tive correlation (r =−0.06) (Fig. 6C) indicates both that transcript
abundance is not gene length dependent and that the overlap of
TOP2A-cleaved coding genes with coding genes having higher lev-
els of expression (Fig. 5A) is not affected by gene length. In fact,
when coding genes within the length categories abovewere subdi-
vided by whether genic CCR signal strength (HP10M) was more or
less than average, the genes with higher than average CCR signal
strengthwithin each length category had significantly higher tran-
script abundance (Fig. 6D). These data demonstrate that TOP2A
cleavage events are independently correlated with the length of
coding genes and their level of expression. Together with the
CCR enrichment in more distal regions of gene bodies (Fig. 5D),
they further reinforce a role for TOP2A cleavage in transcription
elongation.
TOP2A cleavage functions in lincRNA transcription
The TOP2ACCR enrichment in lincRNAs (Fig. 3B) raised questions
about whether TOP2A cleavage events are important for lincRNA
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transcription. Like the bimodal coding transcript distribution (Fig.
5A), a probability density plot generated by extracting lincRNA
transcript abundance data from the two RNA-seq data sets for
K562 cells (Bansal et al. 2014) showed a bimodal distribution of
lincRNA transcript abundance and, as expected, globally lower
lincRNA expression compared with coding gene expression (Fig.
5A; Supplemental Fig. S9). For each treatment tested, TOP2A-
cleaved lincRNA loci were more likely to have moderately abun-
dant transcripts. Just as for coding genes, CCR signal strength in-
creased with increasing length, and lincRNA expression and
length showed a weak negative correlation (r =−0.10). Across the
range of lengths, lincRNAs with a higher than average CCR signal
strength also exhibited higher levels of transcription. Thus, as for
coding genes, TOP2A cleavage of lincRNAs is independently
Figure 4. TOP2A cleavage in genes involved in oncogenic translocations. (A, left) Larger proportions of genes containing CCRs in KMT2A recombinome
comparedwith all coding genes. (∗∗) P < 1 × 10−5 for DMSO, VP16, mitoxantrone; (∗) P < 1 × 10−4 for pBQ, genistein; χ2 test. (A,middle) Larger proportions
of genes containing TOP2A DSBs in KMT2A recombinome compared with all coding genes. (∗) P < 0.05 for DMSO, mitoxantrone, pBQ, genistein; (∗∗) P =
0.00027375 for VP16; χ2 test. (A, right) Larger proportions of cancer fusion genes (Mitelman et al. 2016) containing CCRs comparedwith all coding genes.
(∗∗∗) P < 2.2 × 10−16; χ2 test. Amplified samples; same treatments merged where applicable (Supplemental Table S1). (B–E) CCR signals (HP10M) in indi-
vidual amplified samples along regions of genes involved in leukemia-associated translocations linked to TOP2 poisons (bars). Panels show sonicated input
and different treatments (top in panels). Gene models from GRCh38/hg38 in the UCSC Genome Browser (bottom) (Kent et al. 2002; http://genome.ucsc.
edu/) correspond to tracks shown. (B) KMT2A. Bar, 8.3-kb bcr spanning exon 7 through exon 13 positions 118,481,830–118,490,167; NC_000011.10.
(C) PML. Left bar, 1.45-kb intron 3 bcr, positions 74,023,409–74,024,856; right bar, 1.06-kb intron 6 bcr, positions 74,033,415–74,034,477;
NC_000015.10. (D) RARA. Bar, 16.9-kb intron 2 bcr, positions 40,332,397–40,348,315; NC_000017.11. (E) RUNX1. Left bar, 25-kb intron 6 bcr, positions
34,859,473–34,834,602; right bar, 35-kb intron 7 bcr, positions 34,834,409–34,799,463; NC_000021.9.
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associated with both length and expression levels (Supplemental
Fig. S9).
TOP2A CCRs are associated with open chromatin and enhancer
elements
Also, by using existing data for K562 cells (The ENCODE Project
Consortium 2012), we discovered that DNase I cleavage signals
in DNase I hypersensitive sites (DHSs) were stronger in DHSs
that overlap with TOP2A CCRs compared with nonoverlapping
DHSs (Fig. 7A). Because DHSs are marks of open chromatin
(Thurman et al. 2012), this finding suggests that TOP2A cleavage
aids in maintaining open chromatin. Furthermore, the stronger
DNase I signals in DHSs overlapping with TOP2A CCRs in
the TOP2 poison–treated samples (Fig.
7A) imply that TOP2A DNA damage
with these compounds favors open
chromatin.
H3K4me1 and H3K27ac are marks
of active enhancers. We discovered that
the signals for these marks were signifi-
cantly enriched directly at the center of
TOP2A CCRs, including marks of both
strong (H3K4me1/H3K27ac) and weak
(H3K4me1 alone) enhancers (Fig. 7B,C;
Supplemental Fig. S10; Creyghton et al.
2010). These data indicate that TOP2A
cleavage is also targeted to active enhanc-
er elements.
Clustering of chromatin features
overlapping with CCRs
We further characterized the chromatin
features that impact CCR location by ac-
cessing data for histone marks, POLR2A
sites, and DHSs (The ENCODE Project
Consortium 2012) and conducting a ge-
nome-wide principal component analy-
sis (PCA) (Huff et al. 2010). Five clusters
were distinguished by two PCs (Fig. 7D).
Along PC1, clusters of gene repression
marks H3K9me3 and H3K27me3 (dark
blue and green, respectively) are separat-
ed from clusters of marks known to posi-
tively affect expression, including DHSs
and POLR2A sites (light blue) and
H3K36me3, H3K9me1, H3K79me2, and
H4K20me1 (purple). Along PC2, we
found an intriguing separation between
clusters of marks tagging actively ex-
pressed genes (light blue, purple) from
a cluster of enhancer marks (e.g.,
H3K27ac, H3K4me1) and other gene ac-
tivating elements (red). Thus, the CCRs
overlapping with marks of gene bodies
undergoing transcription (Fig. 5B,C)
are distinct from those overlapping
with marks of enhancers (Fig. 7B,C;
Supplemental Fig. S10). This PCA indi-
cates that discrete genomic environ-
ments contain CCRs associated with gene bodies or gene
activating elements, and reinforces that active portions of the ge-
nome are enriched in CCRs.
Discussion
We developed a procedure to comprehensively map TOP2A cleav-
age sites genome-wide by high-throughput sequencing of DNA
ends released from immunopurified cleavage complexes that sur-
mounts inherent limitations in cellular approaches to study
TOP2 cleavage (Sano et al. 2008; Iacovoni et al. 2010; Crosetto
et al. 2013; Baranello et al. 2014; Pang et al. 2015). The procedure
identifies +1 positions in cleavage complexes at single-base preci-
sion by coupling a new use of the phosphodiesterase activity in
0.950
0.975
1.000
1.025
0 25 50 75 100
lo
g 2
(P
O
LR
2A
 S
ig
na
l)
C
Gene Body
C
C
R
 R
at
io
 (%
)
D
A
0.950
1.000
1.050
DMSO
0.96
1.00
1.04
VP16
0.95
1.00
Mitoxantrone
0.95
1.00
1.05
1.10
pBQ
Genistein
0.00
0.05
0.10
0.15
0.20
Pr
ob
ab
ili
ty
 D
en
si
ty
lo
g 2
(H
3K
36
m
e3
 S
ig
na
l)
B
−10 −5 0 5 10
Average Transcript Abundance (Log2 RPKM)
All genes
DMSO
VP16
Mitoxantrone
pBQ
Genistein
0
2
4
6
DMSO
Y N
***
VP16
Y N
***
Mitoxantrone
Y N
***
pBQ
Y N
***
Genistein
Y N
***
7
8
9
10
11
Y N
***
Y N
***
Y N
***
Y N
***
Y N
***
DMSO pBQMitoxantrone GenisteinVP16
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et al. 2014) were used to plot transcript abundance. Note skew of CCR-containing genes toward peak
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windows. Graphs display CCRs/window relative to total. Note distribution in middle and 3′ ends with
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same treatments merged where applicable (Supplemental Table S1).
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CIP preparations—to detach DNA from cleavage complexes—with
the power of high-throughput sequencing.
We address the potential for low DNA yield from either low
phosphodiesterase activity of CIP (O’Brien and Herschlag 2001;
Igunnu et al. 2011) or restricted samples by amplifying the released
DNA before library preparation without affecting reproducibility.
Thus, our assay can be used even with limited DNA recovery,
and the selective release of DNA directly from immunopurified
cleavage complexes enhances specificity. The detection of cleav-
age at precise sites also found in vitro and at translocation break-
point hotspots, as well as local base preferences for cleavage
mirroring those in vitro, gave validation to our assay. Also, the
1.3%–3.4% TOP2A DNA DSBs that we found are consistent with
prior studies (Zechiedrich et al. 1989; Muslimovic et al. 2009).
Overall, our methodology achieved the genome-wide identifica-
tion of TOP2A cleavage sites not previously accomplished.
Our procedure avoids the fixation step of conventional ChIP-
seq for two reasons. First, the active site tyrosine residues of TOP2
are already covalently attached to the DNA by phosphodiester
linkage. Second, fixation would preclude distinguishing noncova-
lent TOP2 DNA binding from the TOP2 covalently bound to DNA
in cleavage complexes.
Ourmethod differs from the procedure that employs TDP2 to
release the DNA from the cleavage complex (Cowell et al. 2012).
TDP2 hydrolyzes 5′ phosphodiester bonds specifically but requires
TOP2 proteolytic degradation to expose the protein–DNA linkage
(Gao et al. 2014; Ashour et al. 2015). The use of CIP to release the
DNA is simpler because it is carried out directly on the bead-bound
TOP2 without protease digestion. It is also critical for the enzyme
used to hydrolyze the phosphodiester bond to havehigh activity at
TOP2 SSNs as well as DSBs because most cellular TOP2 cleavage
sites are SSNs (Zechiedrich et al. 1989; Muslimovic et al. 2009;
data from the present study in Supplemental Table S1 and
Supplemental Fig. S2). However, TDP2 has low activity at TOP2
SSNs compared with TOP2 DSBs (Gao et al. 2014).
Our observations expand working models of functional
TOP2A–DNA interactions. Beyond confirming that TOP2 poisons
confer nonrandom and different local base cleavage preferences
(Capranico and Binaschi 1998), we discover that TOP2A cleavage
sites cluster in CCRs that display evolutionary conservationwithin
the human population. Also, the CCRs exhibit favoritism for in-
trons and lincRNAs comprising transcriptionally active genome
elements.
We follow the standard ChIP-seq practice of only retaining
uniquely mapping reads (Kellis et al. 2014) to identify CCRs and
specifically guard against falsely calling CCRs in repeats caused by
multimapping. Despite the resultant reduction in reads within re-
peats, our analysis still identifies CCRs within repetitive elements.
However, we cannot exclude that uniquely mapping reads are un-
derrepresented in longer repeats due to the limits of read length.
Like TOP2A cleavage sites, oncogenic translocations are bi-
ased toward introns, and we discover that not only KMT2A recom-
binome genes but also all known cancer fusion genes are more
likely to be cleaved by TOP2A, raising the intriguing possibility
that TOP2A has a previously unrecognized broader role in trigger-
ing translocations. The TOP2 poisons enhance cleavage in regions
of KMT2A, PML, RARA, and RUNX1 that are often translocated in
leukemia, suggesting that the sequence preferences for TOP2 poi-
son–induced cleavage set the stage for translocations. We find ev-
idence in cells that TOP2A cleavage can generate the DSBs and
Figure 6. Independent associations of CCR signal strength with coding gene length and transcript abundance. (A,B) Correlation between length and
genic CCR signal strength (HP10M) in DMSO-treated (A) and VP16-treated (B) samples. Gene length from GRCh38/hg38 by categories on x-axis.
(Boxes) 25th to 75th percentiles; (whiskers) fifth to 95th percentiles; (horizontal lines) median for each length interval. χ2 test P-values, top right in panels.
Amplified samples; same treatments merged (Supplemental Table S1). (C) Scatter plot of protein-coding transcript abundance versus gene length based
on two RNA-seq data sets for untreated K562 cells (GEO accession number GSE46718) (Bansal et al. 2014) and gene length from GRCh38/hg38. Smooth
line was predicted by the gammethod (Supplemental Methods). (Shading) Confidence interval around smoothed trend line. Genes with RPKM > 0.1 plot-
ted. r-value (top right) shows slight overall negative correlation. (D) Box and whisker plots of genic CCR signal strength versus transcript abundance within
indicated length categories subdivided based on </> average genic CCR signal strength. (∗) P < 0.05; χ2 test. Note correlation between genic CCR signal
strength and transcript abundance across all lengths. Union set of all amplified samples (Supplemental Table S1).
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SSNs required to create the breakpoint junctions found in treat-
ment-related (Lovett et al. 2001;Whitmarsh et al. 2003) and infant
(Gillert et al. 1999; Raffini et al. 2002) KMT2A-R leukemias, respec-
tively, including that etoposide causes a higher proportion of
KMT2A recombinome genes to have TOP2A DSBs relative to all
genes in the genome. At a single-nucleotide scale, we discover
TOP2A cleavage sites at translocation breakpoints, including at
the KMT2A-R treatment–related leukemia translocation break-
point hotspot, supporting the model in which TOP2A DNA dam-
age is the direct precursor lesion to leukemogenic translocations.
This study also uncovers new relationships between TOP2A
cleavage and coding gene and lincRNA transcription. Unlike the
bimodal distribution of transcript abundance, we show skews of
TOP2A-cleaved loci toward more highly expressed coding genes
and a lincRNA subset with moderately abundant transcripts. We
find that in coding genes, TOP2A CCRs are spatially enriched in
the distal regions of gene bodies, suggest-
ing that TOP2A cleavage is important for
transcriptional elongation, and we dis-
cover that the TOP2 poisons etoposide,
mitoxantrone, and genistein cause prox-
imal shifts in this spatial distribution.
Whereas transcript abundance and
length are unrelated, in coding and
lincRNA loci alike we observe that
TOP2A CCR signal strength is indepen-
dently associated with gene length and
with the abundance of transcripts pro-
duced by genes of all length categories.
Additionally, we discover that genes
with TOP2A CCRs have stronger signals
for the marks of transcription elongation
POLR2A and H3K36me3 (Li et al. 2002;
Strahl et al. 2002). Others previously ob-
served that long genes contain a higher
density of supercoiled chromatin, which
stalls POLR2A during transcription elon-
gation (Joshi et al. 2012). Given that
genes with CCRs display higher tran-
scriptional activity, the greater CCR sig-
nal strength with increasing length, yet
lack of correlation between length and
transcript abundance, suggests that
greater TOP2A cleavage is required to re-
lax the DNA supercoils in long coding
and lincRNA loci during transcription.
Thus, we conclude that TOP2A
CCRs play an important role in transcrip-
tion elongation of coding genes and
lincRNA loci. The discoveries of TOP2A
in the Pol II complex and TOP2A require-
ment for chromatin dependent in vitro
transcription (Mondal and Parvin 2001)
are in concert with this conclusion,
as are the enriched TOP2 binding in
highly transcribed Saccharomyces cerevi-
siae genes (Sperling et al. 2011) and the
reduced expression of longer genes
with yeast Top2 inhibition (Joshi et al.
2012). Although murine ES cells display
TOP2A binding at promoters (Thakurela
et al. 2013), we do not find TOP2A CCR
enrichment at promoters. Because TOP2A binding does not neces-
sarily equate to cleavage (Mueller-Planitz and Herschlag 2007; Lee
et al. 2012), our study and themouse ES cell study together suggest
that TOP2A begins to track supercoil accumulation starting at the
promoter but then cleaves well into the gene body during tran-
scription elongation.
Consistent with roles of TOP2A cleavage in translocations
and transcription, TOP2A CCRs are correlated with stronger
DNase I sites tagging open chromatin. We also uncover another
subset of TOP2A CCRs correlated with the H3K4me1/H3K27ac
and H3K4me1 marks of strong and weak enhancers (Creyghton
et al. 2010) that suggest a previously unsuspected function of
TOP2A in long-range regulation of gene activation. Our discovery
that marks of active transcription along gene bodies, marks of
open chromatin, and marks of enhancers colocalize with TOP2A
CCRs within separate genomic environments implicates TOP2A
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CCRs as chromatin remodeling orchestrators alongside multiple
chromatin features.
Altogether our data indicate a new, more general DNA-dam-
aging role of TOP2A cleavage in oncogenic translocations beyond
those attributed to exposures to TOP2 poisons in leukemia (Felix
2012; Gole and Wiesmuller 2015) and a modular organization of
TOP2A CCRs with factors in the epigenome and transcriptional
machinery as a fundamental feature of human cells that impacts
translocations and transcription. Because our methodology was
developed in a transformed leukemia cell line, in its further appli-
cations, it will be important to compare genome-wide TOP2 cleav-
age patterns between isoforms in different primary cell types
representing normal development and disease states to build on
these discoveries.
Methods
Cell treatment and library preparation
Vehicle or TOP2 poison–treated K562 cells were lysed with RIPA
buffer. The lysates were sonicated to fragment the DNA to 100–
1500 bp and frozen overnight. TOP2A was immunocaptured
with anti-TOP2A and Protein G magnetic beads, the bead-bound
fraction separated, and nonbound fractions subjected to immuno-
capture again twice. The bead-bound fractions were combined and
treated with CIP (New England Biolabs) to detach the TOP2A-
bound DNA from cleavage complexes. The released DNA and in-
put DNA were purified and used directly for library synthesis
with an Illumina TruSeq ChIP library kit or preamplified with a
SEQXE kit (Sigma-Aldrich) before preparing libraries for sequenc-
ing (Supplemental Fig. S1; Supplemental Methods).
Data analysis
Raw reads were aligned to the human genome version GRCh38/
hg38 (released 12-2013). Reads that mapped uniquely were re-
tained and normalized to RP10M (reads per 10 million reads
mapped). Correlation coefficients of reads in 10-kb windows
were determined for biological replicates. Criteria for calling
TOP2A cleavage sites and CCRs, and definitions of genic TOP2A
CCR signal strength, were as described in the Results. CCRs from
similarly treated preamplified samples or from all preamplified
samples across treatments were merged into union sets.
Statistical tests used for cleavage site analyses and for comparisons
of CCRs with human SNP data (The 1000 Genomes Project
Consortium 2015), genomic elements, transcript abundance,
and chromatin features and the method of converting data sets
from the ENCODE Project Consortium 2012 for chromatin fea-
tures (The ENCODE Project Consortium 2012) from GRCh37/
hg19 to GRCh38/hg38 are in the Supplemental Methods.
Data access
All data from this study have been submitted to the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE79593. All data are also available at
the UCSC Genome Browser (see Data Access Instructions in the
Supplemental Methods) (Kent et al. 2002; http://genome.ucsc.
edu/).
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